Fuzhong Qin, MD, PhD

Research Professor, Medicine

Fuzhong Qin
617.638.8051
650 Albany St Evans Biomed Research Ctr

Biography

Dr. Qin is a Professor of Cardiovascular Medicine at the Chobanian and Avedisian School of Medicine. He is the Director of the Physiological Core Laboratory in the Myocardial Biology Unit / Cardiovascular Medicine Section. He is also the Director of the Echocardiography Core in the Whitaker Cardiovascular Institute. Dr. Qin’s research has focused on the cellular and molecular mechanisms of myocardial remodeling and pathophysiology of heart failure, and in particular, the role of reactive oxygen species. They are investigating the effects of catalase overexpression or pharmacological intervention on left ventricular remodeling and dysfunction in transgenic mouse models of heart failure induced by G(alpha)q overexpression as well as mouse models of human heart failure induced by chronic pressure overload or myocardial infarction and diet-induced metabolic heart disease. Dr. Qin has expertise (scientific) in a) oxidative stress, myocyte apoptosis, and apoptosis-related signal transduction pathways, b) oxidative stress, oxidative protein modifications of SERCA2, intracellular calcium transients and myocyte contractile function, c) oxidative stress, myocyte hypertrophy and myocardial diastolic dysfunction. He also has expertise (technical) in the animal models (mice, rats, rabbits and dogs) of myocardial ischemia / reperfusion, coronary artery ligation-induced myocardial infarction and failure, and ascending aortic constriction-induced myocardial hypertrophy and failure, conventional echocardiography, mitral inflow and tissue Doppler echocardiography, in vivo hemodynamics, ex vivo Langendorff isolated heart perfusion, measurements of intracellular calcium concentration and contractile function in isolated myocytes, myocyte culture, histological measurements and biochemical measurements.

Other Positions

  • Member, Whitaker Cardiovascular Institute, Boston University
  • Boston Medical Center

Websites

Education

  • Datong Medical College, MD
  • Shanxi Medical University, PhD

Publications

  • Published on 1/31/2023

    Croteau D, Baka T, Young S, He H, Chambers JM, Qin F, Panagia M, Pimentel DR, Balschi JA, Colucci WS, Luptak I. SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy. Biomed Pharmacother. 2023 Apr; 160:114310. PMID: 36731341.

    Read at: PubMed
  • Published on 6/25/2021

    Croteau D, Luptak I, Chambers JM, Hobai I, Panagia M, Pimentel DR, Siwik DA, Qin F, Colucci WS. Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice. J Am Heart Assoc. 2021 07 06; 10(13):e019995. PMID: 34169737.

    Read at: PubMed
  • Published on 10/20/2020

    Goodman JB, Qin F, Morgan RJ, Chambers JM, Croteau D, Siwik DA, Hobai I, Panagia M, Luptak I, Bachschmid M, Tong X, Pimentel DR, Cohen RA, Colucci WS. Redox-Resistant SERCA [Sarco(endo)plasmic Reticulum Calcium ATPase] Attenuates Oxidant-Stimulated Mitochondrial Calcium and Apoptosis in Cardiac Myocytes and Pressure Overload-Induced Myocardial Failure in Mice. Circulation. 2020 12 22; 142(25):2459-2469. PMID: 33076678.

    Read at: PubMed
  • Published on 9/9/2020

    Croteau D, Qin F, Chambers JM, Kallick E, Luptak I, Panagia M, Pimentel DR, Siwik DA, Colucci WS. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease. JACC Basic Transl Sci. 2020 Sep; 5(9):916-927. PMID: 33015414.

    Read at: PubMed
  • Published on 7/1/2019

    Luptak I, Croteau D, Valentine C, Qin F, Siwik DA, Remick DG, Colucci WS, Hobai IA. Myocardial Redox Hormesis Protects the Heart of Female Mice in Sepsis. Shock. 2019 07; 52(1):52-60. PMID: 30102640.

    Read at: PubMed
  • Published on 6/25/2019

    Luptak I, Qin F, Sverdlov AL, Pimentel DR, Panagia M, Croteau D, Siwik DA, Bachschmid MM, He H, Balschi JA, Colucci WS. Energetic Dysfunction Is Mediated by Mitochondrial Reactive Oxygen Species and Precedes Structural Remodeling in Metabolic Heart Disease. Antioxid Redox Signal. 2019 09 01; 31(7):539-549. PMID: 31088291.

    Read at: PubMed
  • Published on 2/1/2018

    Luptak I, Sverdlov AL, Panagia M, Qin F, Pimentel DR, Croteau D, Siwik DA, Ingwall JS, Bachschmid MM, Balschi JA, Colucci WS. Decreased ATP production and myocardial contractile reserve in metabolic heart disease. J Mol Cell Cardiol. 2018 03; 116:106-114. PMID: 29409987.

    Read at: PubMed
  • Published on 7/24/2017

    Ho JE, Rahban Y, Sandhu H, Hiremath PG, Ayalon N, Qin F, Perez AJ, Downing J, Gopal DM, Cheng S, Colucci WS. Preclinical Alterations in Myocardial Microstructure in People with Metabolic Syndrome. Obesity (Silver Spring). 2017 Sep; 25(9):1516-1522. PMID: 28737258.

    Read at: PubMed
  • Published on 10/20/2016

    Xu XJ, Babo E, Qin F, Croteau D, Colucci WS. Short-term caloric restriction in db/db mice improves myocardial function and increases high molecular weight (HMW) adiponectin. IJC Metab Endocr. 2016 Dec; 13:28-34. PMID: 27942464.

    Read at: PubMed
  • Published on 1/11/2016

    Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, Siwik DA, Miller EJ, Liesa M, Shirihai OS, Pimentel DR, Cohen RA, Bachschmid MM, Colucci WS. Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease. J Am Heart Assoc. 2016 Jan 11; 5(1). PMID: 26755553.

    Read at: PubMed

View 22 more publications: View full profile at BUMC

View all profiles